Fabio Catalano

8PUBLICATIONS
46CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

Alessandra Damassi, Malvina Cremante, Alessio Signori

|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.

Sara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini

|Apr 13, 2023
Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives.

Fabio Catalano, Malvina Cremante, Bruna Dalmasso

|Jan 04, 2023
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report.

Veronica Murianni, Luigi Cerbone, Pasquale Rescigno

|Sep 23, 2022
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.

Alberto Puccini, Marta Ponzano, Bruna Dalmasso

|Mar 10, 2022
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.

Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano

Pageof 2

Frequent Collaborators

7 joint publications

Giuseppe Fornarini

6 joint publications

Sara Elena Rebuzzi

6 joint publications

Giuseppe Luigi Banna

5 joint publications

Veronica Murianni